Scilex Holding Company 8-K Summary
Business context and reporting period
Scilex Holding Company filed a Current Report on Form 8-K dated November 10, 2022, with the report signed November 17, 2022. The filing documents the completion of the domestication and business combination between Vickers Vantage Corp. I and Legacy Scilex Holding Company. Vickers was the predecessor shell company; following closing, it changed its name to Scilex Holding Company and ceased to be a shell company.
- The transaction closed on November 10, 2022, after shareholder approval.
- Scilex became the successor issuer to Vickers under Exchange Act Rule 12g-3(a).
- Common stock and warrants began trading on Nasdaq on November 11, 2022 under SCLX and SCLXW, respectively.
- The filing incorporates Legacy Scilex financial statements for the three and nine months ended September 30, 2022 and 2021, as well as pro forma combined information, but the provided filing text does not include the underlying revenue or earnings figures.
Transaction and capital structure
- Legacy Scilex became a wholly owned subsidiary of New Scilex upon completion of the merger.
- The aggregate merger consideration was $1.5 billion, calculated using an Exchange Ratio of 0.673498. Specified indebtedness used in the calculation was reported as zero.
- Sorrento Therapeutics contributed $290.6 million of intercompany indebtedness in exchange for 29,057,097 shares of Legacy Scilex Series A Preferred Stock. Those shares converted into 29,057,097 shares of New Scilex Series A Preferred Stock and related common-stock consideration.
- Immediately after closing, New Scilex had 141,098,856 common shares, 29,057,097 Series A preferred shares, and 8,253,331 warrants outstanding.
- Sorrento beneficially owned 138,830,590 common shares, all 29,057,097 preferred shares, and approximately 96.9% of total voting power as of November 10, 2022. Its common-share figure included 3,104,000 shares subject to warrants exercisable within 60 days.
- Sponsors forfeited 2,736,000 private-placement warrants and transferred 3,104,000 warrants to Sorrento.
- Sponsors received 533,057 common shares in exchange for contributing $5.3 million of Vickers obligations.
Revenue, profit, cash flow, margins, debt and liquidity
The filing text provided does not clearly state consolidated revenue, net income or loss, operating cash flow, gross or operating margins, cash balances, debt balances, or liquidity metrics for the September 30, 2022 period. Those amounts are contained in the incorporated Legacy Scilex financial statements, MD&A and pro forma exhibits rather than reproduced in the supplied text.
- The filing describes the $290.6 million intercompany indebtedness contribution by Sorrento, but does not present a complete post-closing debt or liquidity schedule.
- No dividend has been paid on common stock to date. Future dividends are discretionary and depend on revenues, earnings, capital requirements and general financial condition.
Material changes versus the prior comparable period
- The most significant change was the conversion of Vickers from a shell company into the operating public-company parent of Scilex.
- Vickers’s public units separated into their component securities and were delisted; common stock and warrants continued trading separately on Nasdaq.
- Ownership and voting control became highly concentrated in Sorrento, which held approximately 96.9% of total voting power at closing.
- The company adopted a new Delaware charter, bylaws and Series A Preferred Stock designation, and approved new equity incentive and employee stock purchase plans.
- WithumSmith+Brown, PC was dismissed as Vickers’s independent registered public accounting firm, and Ernst & Young LLP was appointed for the fiscal year ending December 31, 2022. The filing notes a previously disclosed material weakness in Vickers’s internal control over financial reporting.
Guidance, outlook, management commentary, risks and unusual items
The filing does not provide quantitative revenue, earnings or cash-flow guidance. It states that future performance depends on, among other matters, financing availability, realization of expected transaction benefits, competition, regulatory approvals, product development, intellectual-property protection, profitable growth, Nasdaq listing compliance and trading liquidity.
- Forward-looking statements are subject to substantial risks and uncertainties, including regulatory, judicial and legislative changes, product-candidate approval risks, competition from larger pharmaceutical companies and the ability to execute the business plan.
- The filing cautions that COVID-19 and other unknown or immaterial risks could amplify uncertainties.
- Existing holders received registration rights subject generally to a 180-day transfer restriction, subject to specified exceptions and earlier termination in certain transactions.
- New Scilex entered into indemnification agreements with its directors and executive officers.
- The company’s new executive officers were Jaisim Shah, President and Chief Executive Officer, and Elizabeth Czerepak, Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary.
Important facts for investors to verify
- Review Exhibit 99.3 for actual September 30, 2022 and 2021 revenue, operating results, cash flows, debt and liquidity.
- Review Exhibit 99.4 for management’s discussion of operating trends, financing needs, going-concern considerations and material changes.
- Review Exhibit 99.5 for pro forma capitalization and the accounting effects of the business combination.
- Confirm the rights, preferences and voting effects of the 29,057,097 Series A preferred shares held by Sorrento.
- Assess dilution from the 8,253,331 outstanding warrants, stock options, equity plans and other rollover equity instruments.
- Monitor the previously disclosed material weakness in internal control over financial reporting and the transition from Withum to Ernst & Young.
- Review the merger, contribution, warrant-transfer and registration-rights agreements for restrictions, related-party effects and potential future share-sale pressure.